Molecular Mechanisms of Proteinuria in Focal Segmental Glomerulosclerosis

Yumeng Wen, Sapna Shah and Kirk N. Campbell*

Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States

Focal segmental glomerulosclerosis (FSGS) is the most common primary glomerular disease resulting in end-stage renal disease in the USA and is increasing in prevalence worldwide. It is a diverse clinical entity with idiopathic, genetic, metabolic, infectious, and other causes that culminate in a characteristic histologic pattern of injury. Proteinuria is a hallmark of FSGS as well as other primary and secondary glomerular disorders. The magnitude of proteinuria at disease onset and during treatment has prognostic implications for renal survival as well as associated cardiovascular morbidity and mortality. Significant advances over the last two decades have shed light on the molecular architecture of the glomerular filtration barrier. The podocyte is the target cell for injury in FSGS. A growing list of disease-causing gene mutations encoding proteins that regulate podocyte survival and homeostasis has been identified in FSGS patients. Several pathogenic and regulatory pathways have been uncovered that result in proteinuria in rodent models and human FSGS. The recurrence of proteinuria and FSGS after kidney transplantation is supporting evidence for the role of a circulating permeability factor in disease pathogenesis. These advances reviewed herein have significant implications for disease classification and therapeutic drug development for FSGS.

Keywords: podocyte, focal segmental glomerulosclerosis, HIVAN, soluble urokinase-type plasminogen activator receptor, podocin

INTRODUCTION

The glomerular filtration barrier is composed of fenestrated endothelial cells, the glomerular basement membrane (GBM), and podocytes, terminally differentiated epithelial cells connected by interposed slit diaphragms between actin-rich foot processes (1). Seminal studies by Farquhar and Palade highlight the role of the GBM in excluding molecules of the size and negative charge of albumin from the urine under normal conditions (2). Though proteinuria can result from injury to any of these components, experimental nephrosis was initially described as mainly affecting the visceral epithelium with loss of podocyte foot processes, reduction and modification of the "urinary slits" (interposed slit diaphragm), and intracellular accumulation of vacuoles and protein absorption droplets (3, 4). Positional cloning of the NPHS1 gene encoding nephrin, a vital component of the slit diaphragm, was a landmark event that initiated the era of molecular discovery of the complex molecular architecture of the podocyte (5). Wiggins et al. performed elegant studies showing that in a diphtheria toxin rat model, podocyte loss of more than 20% results in a low-level-sustained proteinuria. Loss greater than 40% directly causes a high-level proteinuria, a decreased renal function, and lesions of focal segmental glomerulosclerosis (FSGS) (6). Podocyte loss triggers a cascade involving tuft adhesions of bare areas of GBM to Bowman's capsule, a nidus for sclerosis development that can progress to segmental sclerosis (7). Rather than a disease, FSGS should be considered a
histologic pattern of glomerular injury resulting from podocyte loss. It describes not only primary podocyte injury but also a lesion that occurs as a secondary process such as hypertensive and diabetic nephropathy (DN). Clinically and genetically heterogeneous, FSGS is characterized by segmental sclerosis of the glomerular capillary tuft, with or without deposition of IgM and complement C3 (8). The pathogenesis of FSGS is multifactorial, thereby complicating classification efforts and therapeutic approaches. The contribution of circulating permeability factors has been suggested for four decades with the recurrence of FSGS after kidney transplantation potentially occurring within hours (9, 10). Separately, many genes identified in patients with familial and sporadic FSGS encode essential podocyte proteins (11). Viral nephritides, HIV in particular, has been associated with collapsing FSGS (12).

This review discusses the knowledge to date of the underlying pathogenesis of podocyte injury leading to proteinuria and FSGS. We focus on the contributions of putative circulating factors, gene mutations, and viral infections.

**CIRCULATING FACTORS**

The high recurrence rate of FSGS post transplant (estimated at 30–40%) suggests the presence of a circulating factor in recipients. A pivotal study by Savin et al. showed that plasma from patients with recurrent FSGS could increase the glomerular permeability to albumin in an *in vitro* assay. Plasmapheresis was associated with a reduced proteinuria as well as a reduced glomerular permeability (13). Gallon presented an interesting case of a kidney-transplant patient with recurrent FSGS (14). The allograft kidney regained function with a reduction in proteinuria after the graft was removed and re-transplanted to another patient whose ESRD was due to diabetes mellitus. In addition, an infant born to a mother with primary FSGS developed transient proteinuria, suggesting a circulating factor crossing the placenta leading to proteinuria (15). These studies well illustrate the existence of a circulating factor, but the nature and source of such a factor remained unclear. Several putative factors have been proposed including soluble urokinase-type plasminogen activator receptor (suPAR), CLC-1, Apolipoprotein A1, active protease, and anti-CD40.

**Soluble Urokinase-Type Plasminogen Activator Receptor**

Of the putative factors, the role of urokinase-type plasminogen activator receptor (uPAR) and its soluble form (suPAR) have been the most studied (16, 17). uPAR is a glycosylphosphatidylinositol (GPI)-anchored three-domain (DI, DII, and DIII) protein. Apart from being a receptor for urokinase, uPAR also forms signaling complexes with various transmembrane proteins including integrin and is involved in non-proteolytic pathways. The soluble form suPAR can be released by the cleavage of GPI anchor. In Wei’s study, uPAR was upregulated in the glomeruli from both DN and FSGS. Using uPAR knockout (Plaur−/−) mice, model they showed that lipopolysaccharide (LPS)-induced proteinuria was uPAR-mediated, and uPAR upregulation following LPS stimulation led to αvβ3 integrin activation, with subsequent podocyte foot process effacement, increased podocyte motility, and proteinuria (16). The same group subsequently revealed the role of suPAR as a potential pathogenic factor involved in podocyte injury (17). Recombinant suPAR and serum from patients with FSGS recurrence induced αvβ3 integrin activation both *in vitro* and *in vivo*. In uPAR-knockout (Plaur−/−) mice, the supraphysiologic level of endogenous suPAR and exogenous suPAR injection induced αvβ3 integrin activation, resulting in podocyte injury and proteinuria. A recent study (18) has shed light on the source of suPAR production. Myeloid progenitor Gr-1lo cell expansion along with suPAR upregulation and proteinuria was observed in different rodent models for proteinuric kidney disease including DN and nephrotic serum nephritis. Incubating Gr-1lo – Sca-1 + myeloid progenitor cells with LPS led to uPAR expression and suPAR secretion, and injecting these myeloid progenitor cells could induce proteinuria in NSG mice (deficient in mature lymphocytes and natural killer cells). To translate their findings to human disease, the investigators introduced whole peripheral blood mononuclear cells (human hematopoietic cells), drawn from individuals with recurrent FSGS and injected into NSG mice. This approach led to Gr-1lo cell expansion, suPAR upregulation, and proteinuria. However, CD34+-depleted PBMC from these patients failed to induce any proteinuria. This process was distinct from GVHD pathophysiology since T cell-depleted PBMC yielded similar results. Though human homologs of Gr-1lo – Sca-1 + myeloid progenitor cells have not been identified given the lack of Gr-1 or Sca-1 antigen, these findings implicate a common upstream pathway relevant to general CKD. The same investigators recently linked APOL1-risk alleles to the suPAR–β3 integrin activation pathway (19). In this study, G1/G2-risk alleles were demonstrated to activate β3 integrin synergistically with suPAR, inducing autophagosome formation in podocytes and leading to foot process effacement, podocyte detachment, and proteinuria.

These findings have not been without controversy. Conflicting studies have shown that suPAR does not distinguish FSGS from other causes of nephrotic syndrome and that suPAR expression may be nonspecifically increased in the setting of a low eGFR (20–22). These findings have raised questions about the reliability of current ELISA methodology as a diagnostic biomarker for FSGS (23). It is likely that suPAR’s utility is confined to patients with a preserved eGFR. This is supported by the fact that elevated suPAR levels predicted future CKD development in the 3683 subject Emory Cardiovascular Biobank (24). The fact that suPAR was associated with both proteinuric and non-proteinuric CKD in this cohort also highlights the need for additional mechanistic studies on suPAR targets, production, and mechanism of action.

**Other Proposed Circulating Permeability Factors**

**Cardiotrophin-Like Cytokine Factor 1 (CLCF1)**

Proteomic analysis by liquid chromatography tandem mass spectrometry of recurrent FSGS plasma fractions that induce proteinuria in rats and enhance glomerular permeability to albumin led to the identification of CLCF1 (25–27). CLCF1 is a member of the IL-6 cytokine family and is secreted into the circulation as a heterodimer with either cytokine receptor-like factor 1 (CRLF1) or soluble ciliary neurotrophic factor receptor
alpha. This heterodimeric coexpression is essential for efficient CLF1 secretion (28, 29). It has been demonstrated that CLF1 increased glomerular permeability to albumin in a specific manner with anti-CLCF1 monoclonal antibody, blocking this effect and attenuating the effect of FSGS serum (30). CLCF1 appeared to be JAK/STAT dependent with both JAK2 and STAT3 inhibition blocking the ability of CLCF1 to increase glomerular permeability to albumin. Interestingly, heterodimeric CLCF1–CRLF1 also had an inhibitory effect on CLCF1 and FSGS-induced albumin permeability (30). This would suggest that while monomeric CLCF1 is pathogenic, heterodimeric CLCF1 is protective. The study also highlights the need for further exploration of the JAK–STAT pathway in FSGS pathogenesis.

**Anti-CD40 Antibody**

Recently, Delville et al. (31) screened 9,000 antigens in pretransplant sera from 64 patients with or without recurrent FSGS, compared to 34 non-FSGS CKD patients. A panel of antibodies CD40, PTPRO, CGB5, FAS, P2RY11, SNRPB2, and APOL2 could predict posttransplant FSGS recurrence with 92% accuracy. Pretransplant elevation anti-CD40 antibody alone had the best accuracy of 78% in predicting FSGS recurrence. Anti-CD40 antibody caused podocyte injury both in cultured human podocytes and in wild-type mice, and the formation of this antibody may be associated with altered immunogenicity of the CD40 protein in serum among patients with recurrent FSGS. Proteinuria was further enhanced by co-injecting full-length suPAR into wild mice, suggesting that uPAR–αvβ3 signaling pathway may also be involved in anti-CD40 antibody-induced podocyte injury (31). This study was limited by a small sample size with validation required in other recurrent FSGS cohorts.

**Apolipoprotein A-I**

Proteomic analysis of plasma and urine samples performed on patients with recurrent FSGS post transplant identified a high-molecular-weight form of Apolipoprotein A-I, named as ApoA-Ib in 93% of recurrent FSGS urines compared with <5% of those without recurrence, patients with non-FSGS proteinuric diseases, or patients transplanted for familial FSGS. Proteinuria was further enhanced by co-injecting full-length suPAR into wild mice, suggesting that uPAR–αvβ3 signaling pathway may also be involved in anti-CD40 antibody-induced podocyte injury (31). This study was limited by a small sample size with validation required in other recurrent FSGS cohorts.

**Active Proteases**

There is evidence that plasma proteases may have a pathogenic role in recurrent FSGS. Vasodilator-stimulated phosphoprotein (VASP), a molecule involved in actin cytoskeleton organization is phosphorylated in response to exchange plasma from 10 patients with recurrent FSGS (33). VASP phosphorylation was associated with pathogenic-enhanced podocyte motility. Protease inhibitory drug cocktails and silencing of the protease-activated receptor-1 led to the loss of VASP phosphorylation. The source of increased proteases or whether they are enhanced by protease inhibitor loss remains unclear.

**GENETIC ETIOLOGIES OF FSGS**

Beginning with nephrin, the positional cloning of patients and relatives with familial FSGS has enabled the identification of numerous disease-causing podocyte genes (Table 1). They encode podocyte proteins localized to the cell membrane (TRPC6, nucleus (WT1), mitochondria (COQ2 and COQ6), lysosomes (LIMP2), and cytosol (PLCE1) (34–43). The most common mutations encode actin cytoskeletal (INF2, ACTN4, MYO1E) and slit diaphragm (NPHS1, NPHS2, CD2AP) (5, 44–49) proteins, thereby highlighting the essential role of these structures in the maintenance of the glomerular filtration barrier. Mutations in the ACTN4 gene are all in the actin-binding domain of the encoded protein and have a much higher affinity for actin filaments than of the wild-type protein (50). This gain of function produces a rigid cytoskeleton more susceptible to stress and actin network breaking. INF2, a member of the formin family, also regulates the actin cytoskeleton but in a different way. INF2 variants occur in the diaphanous inhibitory domain that is essential in the inhibition of Rho activation (51). Unchecked Rho signaling has therefore been suggested as a potential etiology for podocyte injury in INF2 mutation (51). Indeed, the activation of RhoA in podocytes has been shown to lead to albuminuria, podocyte foot process effacement, and histologic lesions of FSGS (52).

The Rho family small GTPases (RhoA, Rac1, and Cdc42) are essential in actin cytoskeletal dynamics, cell morphology, motility, and adhesion. While overactive RhoA can be deleterious, there is an emerging consensus that a relative predominance of RhoA activity relative to Rac1/Cdc42 favors a more stationary podocyte with intact foot processes (53, 54). Conversely, Cdc42/Rac1 activation is associated with a more motile podocyte phenotype and foot process retraction. Loss of function mutations in the Arhgap24 gene associated with familial FSGS cause increased levels of active Rac1 and Cdc42 and increased podocyte motility (55). Likewise, ARHGDIA mutations in patients with steroid-resistant nephrotic syndrome increase active GTP-bound Rac1 and Cdc42 again resulting in increased podocyte motility reversed with Rac1 inhibitors (56). The slit diaphragm is also intricately connected to podocyte actin cytoskeletal dynamics. CD2AP and nephrin are direct binding partners with CD2AP interacting with actin, cortactin, and the alpha-actinin modulating protein synaptopodin (57, 58). Nck adaptor proteins link nephrin to the actin cytoskeleton (59). The cytoplasmic domain of nephrin contains six conserved tyrosine residues that when phosphorylated facilitates binding to the SH2 domains of Nck, leading to actin polymerization (60). Upregulated nephrin tyrosine phosphorylation has been described in glomerular injury (61), but the involved tyrosine kinase remains undefined.

The onset of proteinuria is variable in genetic disease with autosomal-recessive etiologies generally manifesting clinically in childhood and autosomal-dominant traits in adulthood. Commercially available genetic testing is most likely to identify known disease-causing variants in infants and patients with familial and syndromic disease (62). Exomic and genomic sequencing have the potential to uncover rare novel gene variants even in sporadic disease, but confirming causation typically requires experimental modeling with cell- and animal-based
TABLE 1 | Gene mutations linked to focal segmental glomerulosclerosis (FSGS).

| Gene          | Protein                        | Gene locus | Mode of inheritance | Phenotype                                 |
|--------------|--------------------------------|------------|---------------------|-------------------------------------------|
| Slit diaphragm                                      |                    |            |                     |                                           |
| NPHS1        | Nephrin                       | 19q13.1    | AR                  | Congenital nephrotic syndrome, Finnish type, sporadic FSGS, nephrotic syndrome |
| NPHS2        | Podocin                        | 1q25.31    | AR                  | Minimal change nephropathy, FSGS          |
| CD2AP        | CD2-associated protein         | 6p12       | AD/AR               | AD or AR sporadic adult-onset FSGS        |
| TRPC6        | TRPC6                          | 11q22.1    | AD                  | Adult-onset FSGS                          |
| Actin cytoskeleton and cytosol                      |                    |            |                     |                                           |
| ACTN4        | Alpha-actinin 4                |            | AD                  | Adult-onset FSGS                          |
| MYO1E        | Myosin 1E                      |            | AR                  | Adult-onset FSGS, Charcot–Marie tooth disease |
| ARHGDIA      | Arhgdia                        | 17q25.3    | AR                  | Early-onset nephrotic syndrome or FSGS    |
| PLCE1        | Phospholipase C epsilon 1      | 10p23.33   | AR                  | Early-onset diffuse mesangial sclerosis and FSGS |
| PTPRO        | Receptor-type tyrosine-protein phosphatase-0 | 12p12.3 | AR                  | Childhood FSGS                            |
| Syndromic conditions                                |                    |            |                     |                                           |
| WT1          | Wilms’ tumor 1                 | 11p13      | AD                  | Diffuse mesangial sclerosis and FSGS, Frasier or Denys–Drash syndrome, GU abnormalities |
| LMXB1        | Lim homeobox transcription factor 1B | 9q31.1   | AD                  | FSGS, dystrophic nails, absent or malformed patella |
| tRNA[^1]     | Mitochondrial                  |            | MATernal            | FSGS, tubulointerstitial nephritis         |
| COQ2         | Coenzyme Q2 homolog, prenyltransferase | 4q21.22 | AR                  | FSGS, neurologic, and muscle abnormalities |
| COQ6         | Ubiquinone biosynthesis monoxygenase COQ6 | 14q24.3 | AR                  | FSGS, deafness                           |
| ITGB4        | Integrin B4                    | 17q25.1    | AR                  | FSGS, epidermolysis bullosa               |
| PDSS2        | Decaprenyl diphosphate synthase subunit 2 | 6q21      | AR                  | FSGS or collapsing FSGS                   |
| Glomerular basement membrane                        |                    |            |                     |                                           |
| CD151        | CD151 Antigen                  | 11p15.5    | AD                  | Early FSGS, deafness, β-thalassemia        |
| CUBN         | Cubulin                        | 10p13      | AR                  | Chronic glomerulosclerosis, FSGS, or HIV-associated nephropathy |
| LAMB2        | Laminin beta 2                 | 3p21       | AR                  | Isolated nephrotic syndrome as part of Pierson syndrome |
| Function unknown                                     |                    |            |                     |                                           |
| APOL1        | Apolipoprotein L1              | 22q12.3    | FSGS, hypertensive-associated kidney disease and HIV nephropathy |

models. Identification of disease-causing gene mutations in FSGS has prognostic consequences since these patients are less likely to respond to steroid and calcineurin inhibitor therapy (63). They should perhaps be prioritized for kidney transplantation since disease recurrence is lower (64). Caution is necessary in the clinical application of genetic data, however. It is estimated that only 2.9% of US patients with nephrotic syndrome have a monogenic form of the disease and there is a risk in attributing a pathogenic role to identified variants that could be noncausal (65, 66).

**Apolipoprotein L1 (APOL1)**

Focal segmental glomerulosclerosis occurs with a higher frequency in African Americans largely due to variations in the Apol1 gene encoding APOL1 (67). APOL1 is a plasma factor that lyses the parasite *Trypanosoma b. brucei*. Over time, the parasite evolved into a serum resistance-associated protein (SRA) containing *T. brucei* rhodensiense that cause African sleeping sickness and capable of inactivating and evading Apol1. G1 and G2 Apol1 gene variants evade the SRA and are active against *T. brucei* rhodensiense. In this sense, this is analogous to malaria where the sickle trait is protective against parasitic infection but causes a hemoglobinopathy. Located on chromosome 22, the G1 and G2 alleles confer an increased risk for developing FSGS, hypertensive-associated kidney disease, and HIV nephropathy (68). In some population-based studies, it has been shown that APOL11 variants conferred a 17-fold risk of FSGS and a 29-fold risk of HIVAN (69). Interestingly, 9 of 10 (90%) African American patients with collapsing FSGS in one cohort were noted to have at least one APOL1-risk allele (70). Several recently published studies have increased the understanding of how APOL1 G1 and G2 variants induce podocyte injury. Mice with podocyte-specific expression of either allele develop foot process effacement, proteinuria, and azotemia (71). These variants were found to interfere with endosomal trafficking and autophagic flux within podocytes leading to inflammatory-mediated cell death and glomerulosclerosis. Defects in autophagy have been previously shown to induce podocyte injury, proteinuria, and FSGS (72, 73), and manipulation of autophagic pathways could form the basis for therapeutic targeting of Apol1. These findings were distinct from those published by another group in which podocyte-specific APOL1-G2 transgenic mice developed preeclampsia but not kidney disease (74). The difference could be explained by the level-lower APOL1 levels obtained in the latter model. Other potential mechanisms have been implicated in APOL1-induced podocyte injury based on in vitro studies. In a human embryonic kidney cell, Tet-on system expression of G1 and G2 variants enhanced efflux of extracellular potassium and subsequent activation of stress-activated protein kinases (SAPK), p38 MAPK, and JNK. Interestingly,
cytotoxicity was abrogated by SAPK inhibition and inhibition of K+ efflux (75). ApoL1 has also been postulated to be involved in apoptosis, mitochondrial dysfunction, and energy depletion in other cell-based studies (76–78). Merely carrying high-risk APOL1 variants is not sufficient to cause kidney disease, and significant attention is currently being directed toward identifying second hits in the form of environmental and infectious triggers that promote disease development. The identification of patients lacking APOL1 with a normal phenotype increases the prospect that it can be therapeutically targeted.

**VIRAL-ASSOCIATED DISEASE**

Podocytes can be injured by viruses either directly or by inflammatory cytokine-mediated targeting of podocyte receptors. In this context, HIV has been best studied. The renal expression of HIV genes has long been recognized as a central role in promoting HIVAN pathogenesis (79). HIV infects podocytes, tubular epithelial cells, infiltrating lymphocytes, as well as macrophages. Early studies of animal models, including the classic transgenic Tg26 mouse lines, studies on reciprocal transplantation between Tg26 and wild-type mice as well as podocyte-specific expression of HIV genes have confirmed the pathogenic role for local HIV gene expression in the kidney (80). Podocyte-predominant infection has been associated with podocyte injury, dedifferentiation, and more rapid loss of kidney function, suggestive of an HIV-driven podocyte injury as a primary pathogenic pathway in HIVAN (81). Moreover, the kidney has been shown to be one of the reservoirs for HIV, allowing active viral replication in this compartment apart from blood (82, 83). In HIVAN and collapsing forms of primary FSGS, injured podocytes were found to revert to a developmental program that includes downregulation of cyclin kinase inhibitors, entry into the cell cycle, upregulation of proliferation maker, and loss of mature phenotypic makers, including CD10/CALLA, C3b receptor, GLEPP-1, podocalyxin, synaptopodin, and importantly, WT1 (84–88). This process, termed podocyte dysregulation or podocyte dedifferentiation, is not observed in other proteinuric kidney disease marked by podocyte injury along with foot process effacement, such as minimal change disease and membranous nephropathy.

Cip/Kip family of cyclin kinase inhibitors acts in both G1 and S phases, while p21 also inhibits G2/M phase complexes. In healthy podocytes, p27 and p57 are expressed but p21 is suppressed (85). However, in patients with HIVAN or idiopathic collapsing FSGS, the expression of p27 and p57 is significantly suppressed, along with an increase in pro-mitotic cyclins (cyclin A), an increase in proliferation marker ki-67, and an expression of p21 (84, 85). Interestingly, the decrease in p27 and p57 was also found in histologically normal glomeruli, suggestive of a decrease of anti-mitotic signals preceding morphological change. Moreover, administering cyclin kinase inhibitors is associated with a restoration of normal podocyte phenotype and attenuated HIVAN presentation without any suppression of HIV gene expression (89, 90). Podocyte dedifferentiation is accompanied by the proliferation of parietal epithelial cells (PECs), which express parietal cell marker such as CK8 and PAX2 and lack podocyte markers. Cell bridges to the CK8-positive parietal lining could be observed without any evidence of coexpression of podocyte markers. These findings suggest that glomerular PECs provide a niche for podocyte progenitor cells (12, 91, 92).

Novel mechanisms of HIV-mediated kidney injury have been recently uncovered. Mammalian target of rapamycin (mTOR) has been found to be critical for p53-induced oxidative cell injury with mTOR inhibition protecting against HIV-induced podocyte apoptosis (93). The protective function of mTOR inhibition in HIVAN could be due to the regulation of microRNAs since rapamycin treatment reverses the downregulation of miR99a, miR-100a, miR-199a, miR-200a, miR-200b, miR-429, and miR-141 caused by HIV infection of human podocytes in culture (94). HIV also compromises the podocyte actin cytoskeleton through downregulation of the vitamin D receptor with associated enhanced deleterious intracellular angiotensin II and cathepsin L expression (95).

**Other Viral-Associated FSGS**

Collapsing FSGS has long been associated with parvovirus B19 infection (96, 97). The prevalence of parvovirus DNA infection within renal tissue is associated with idiopathic FSGS and collapsing FSGS compared with other diseases (98). Using *in situ* hybridization techniques, parvovirus B19 DNA was localized at endothelial cells and both visceral and PECs. However, whether this viral infection results in podocyte dysfunction is still a matter of debate (97). CMV has been associated with FSGS (99), but it remains unclear whether this virus directly infects podocytes. The detection of tubuloreticular inclusions in glomerular endothelial cells in CMV infection suggests a pathogenic role for interferon stimulation (100). Susceptible patients may have identifiable genetic risk factors. Indeed, a cohort of patients receiving interferon treatment who developed collapsing FSGS was reported to carry high-risk ApoL1 genotypes. Interferon α, β, and γ treatment of cultured podocytes increased APOL1 expression (101). Upstream of interferons, Toll-like receptor 3 (TLR3) was also shown here to signal through TLR1, NFKB, and JAK kinases in an interferon-independent manner to also increase APOL1 expression where the TLR3 agonist poly:C promotes the binding of transcription factor IRF1/2 and STAT2 at the APOL1 transcription start site (101). These findings highlight the complex interplay between viruses, antiviral defenses, and the APOL1 genotype in the development of HIV and non-HIV-mediated viral FSGS.

**DECREASED NEPHRON MASS**

Low birth weight individuals have long been known to be susceptible to a reduced nephron number and resulting abnormal hemodynamic stress on remaining nephrons (102, 103). Low birth weight is more commonly seen in FSGS patients than in the general population (104). Proteinuria has been recognized in patients with unilateral renal agenesis where the remaining kidney has a reduced nephron number (105). A decreased nephron mass results in glomerular hypertension and hyperfiltration that increase mechanical stretch and injury to podocytes (106, 107). Glomerular hyperfiltration has also been associated with the pathogenesis of obesity-related FSGS (108). Here as with a decreased nephron mass, the activation of
the renin–angiotensin–aldosterone system, the upregulation of TGFβ, and glomerulomegaly contribute to the vicious cycle that leads to proteinuria and FSGS (109, 110). Angiotensin blockers are the mainstay of treatment for patients with proteinuria due to hyperfiltration. There is some evidence that bariatric surgery can normalize proteinuria in patients with obesity-related glomerular disease (111).

**TARGETED THERAPY**

The identification of molecules essential for maintaining podocyte homeostasis has opened the door to targeted therapeutics for FSGS. Indeed, a number of repurposed drugs currently in clinical use have been shown to act directly on podocytes. Steroids protect podocytes from puromycin aminonucleoside-induced injury (112). Rituximab protects podocytes from injury by preserving sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) expression (113). Cyclosporine stabilizes the actin-bundling protein synaptopodin, preventing cathepsin-mediated cleavage (114). Novel target-specific agents being tested at various stages of development include GDC-0879 (115), AC1903 (116), Abatacept (117), Bis-T-23 (118), and cycloRGDfV (17) as summarized in Figure 1.

**CONCLUSION**

Podocyte injury due to circulating factors, gene mutations, infections, and many diverse etiologies culminate in the clinical manifestation of proteinuria and the histologic finding of FSGS. The evidence for a circulating permeability factor has been evolving in recent years, and various studies have suggested the pathogenic role of suPAR and other factors in the development of FSGS. The composition, origin, identity, and synergistic roles of circulating factor(s) remain unclear, representing an area of high unmet clinical need. Increasingly, podocyte-associated gene mutations are being identified in patients with FSGS. Expanded knowledge of the molecular architecture of the glomerular filtration barrier raises the prospect of a targeted therapeutic drug development.

HIV and other viral infections can induce podocyte injury and FSGS with an increasing interest in the enhanced susceptibility conferred by APOL1-risk alleles. The numerous divergent etiologies and pathogenic mechanisms with resulting variable response rates to therapy and recurrence post transplant speak to the need for a reclassification of the disease into more clinically relevant subtypes. Further exploration of the contributions of JAK/STAT, Rho-GTPase, and ApoL1 to podocyte injury and survival could enhance the quest for novel therapeutic agents.

**AUTHOR CONTRIBUTIONS**

YW, SS, and KC conceived the article contents, prepared the manuscript, and endorsed the final draft submitted.

**FUNDING**

This work was supported by R01 DK103022 to KC.
REFERENCES

1. Greka A, Mundel P. Cell biology and pathology of podocytes. *Ann Rev Physiol* (2012) 74:299–323. doi:10.1146/annurev-physiol-020911-153238

2. Farquhar MG, Wissig SL, Palade GE. Glomerular permeability. I. Ferritin transfer across the normal glomerular capillary wall. *J Exp Med* (1961) 113:47–66. doi:10.1084/jem.113.1.47

3. Farquhar MG. Editorial: the primary glomerular filtration barrier—basement membrane or epithelial slit? *Kidney Int* (1975) 8:197–211. doi:10.1038/ki.1975.103

4. Farquhar MG, Palade GE. Glomerular permeability. II. Ferritin transfer across the glomerular capillary wall in nephrotic rats. *J Exp Med* (1961) 114:699–716. doi:10.1084/jem.114.5.699

5. Kestila M, Lenkkeri U, Mannikko M, Lamerin J, McCreary P, Putaala H, et al. Positionally cloned gene for a novel glomerular protein—pnephin—is mutated in congenital nephrotic syndrome. *Mol Cell* (1998) 1:575–82. doi:10.1016/S0977-2765(00)0057-X

6. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, et al. Podocyte depletion causes glomerulosclerosis: diphteria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. *J Am Soc Nephrol* (2005) 16:2941–52. doi:10.1681/ASN.2005010055

7. Kritz W, Gertz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? *Kidney Int* (1998) 54:687–97. doi:10.1046/j.1523-1755.1998.00044.x

8. Woroniecki RP, Kopp JB. Genetics of focal segmental glomerulosclerosis. *Pediatr Nephrol* (2007) 22:638–44. doi:10.1007/s00467-007-0445-y

9. Rai J, Hoyer MJ, Michael AF. Steroid-resistant nephrotic syndrome: recurrence after transplantation. *Ann Intern Med* (1972) 77:581–6. doi:10.2306/mm-1972-774-7-581

10. Hoyer JR, Vernier RL, Najarian JS, Rai J, Simmons RL, Michael AF. Recurrence of idiopathic nephrotic syndrome after renal transplantation. *Lancet* (1972) 2:2343–8. doi:10.1016/S0140-6736(72)91734-5

11. Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis. *Semin Nephrol* (2003) 23:141–6. doi:10.1056/snp.2003.30014

12. Wyatt CM, Klotman PE, D’Agati VD. HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. *Semin Nephrol* (2008) 28:513–22. doi:10.1016/j.snenph.2008.08.005

13. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. *N Engl J Med* (1996) 334:878–83. doi:10.1056/NEJM1996040434341402

14. Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. *J N Engl Med* (2012) 366:1648–9. doi:10.1056/NEJM2012022500

15. Kemper MJ, Wolf G, Müller-Wiefel DE. Transmission of glomerular permeability or epithelial slits? *Cell Biology and Pathology of Podocytes*. (2010) 114:699–716. doi:10.1084/jem.114.5.699

16. Kovesdy CP, Kramarck J. The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine. *EMBO J* (2001) 20:1692–703. doi:10.1093/emboj/20.7.1692

17. Sharma M, Zhu J, Gauchat JF, Sharma R, McCarthy ET, Srivastava T, et al. Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiac enalapril-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. *Trans R Soc* (2015) 166:384–98. doi:10.1098/rsbl.2015.03002

18. Delville M, Sigdel TK, Wei C, Li J, Hsieh S-C, Fournoni A, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. *Sci Transl Med* (2014) 6:256ra136. doi:10.1126/scitranslmed.3008358

19. Lopez-Hellin J, Cantarell C, Jimeno L, Sanchez-Fructuoso A, Puig-Gay N, Guirado L, et al. A form of Apolipoprotein A-I is found specifically in kidney transplantation. *Sci Transl Med* (2013) 5:193ra90. doi:10.1126/scitranslmed.3008538

20. Weinberg P, Conlon PJ, Lynn KL, Farghi MK, Czegczako T, Hawkes AF, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. *Science* (2005) 308:1801–4. doi:10.1126/science.1113191

21. Harris JJ, McCarthy HJ, Ni L, Wherlock M, Kang H, Wetzels JP, et al. Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1. *J Pathol* (2011) 229:660–70. doi:10.1002/path.4149

22. Reiser J, Polu KR, Moller CC, Kenlan P, Altintas MM, Wei C, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. *Nat Genet* (2005) 37:739–44. doi:10.1038/ng1592

23. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. *Science* (2005) 308:1801–4. doi:10.1126/science.1113191

24. Li J, Zhao D, Ding J, Xiao H, Guan N, Fan Q, et al. WT1 mutation and podocyte molecular expression in a Chinese Frasier syndrome patient. *Pediatr Nephrol* (2007) 22:2133–6. doi:10.1007/s00467-007-0579-y

25. Gbadegesin R, Hinkes B, Vlangos C, Mucha B, Liu J, Hopcian J, et al. Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome. *Pediatr Nephrol* (2007) 22:2509–13. doi:10.1007/s00467-006-0377-y

26. Tajima T, Sasaki S, Tanaka Y, Kusunoki H, Nagashima T, Nonomura K, et al. 46.XY phenotypic male with focal segmental glomerulosclerosis caused by the WT1 splice site mutation. *Horm Res* (2003) 60:302–5. doi:10.1159/000074249

27. Denamur E, Bocquet N, Baudouin V, Da Silva F, Veitia R, Peuchmaur M, et al. Mutational analysis of VASP in podocytes via protease activated receptor-1. *J Am Soc Nephrol* (2010) 5:2115–21. doi:10.2215/CJN.03800609

28. Ashraf S, Gheorghe M, Chaki M, Zhou W, Sloan AJ, Z, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. *J Clin Invest* (2011) 121:2013–24. doi:10.1172/JCI45693

29. Borkovic SE, Dibbens LM, Oshlick A, Silver D, Katerolis M, Vears D, et al. Array-based gene discovery with three unrelated subjects shows SCARB2/
LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. *Am J Hum Genet* (2008) 82:673–84. doi:10.1016/j.ajhg.2007.12.019

43. Diomeddi-Camassetti F, DiGiandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, et al. COQ2 nephropathy: a newly described inherited mitochon-
drdiopathy with primary renal involvement. *J Am Soc Nephrol* (2007) 18:2773–80. doi:10.1681/AS1.2006080833

44. Boyer O, Benito G, Gribouval O, Nevo F, Tete MJ, Dantal J, et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulo-
sclerosis. *J Am Soc Nephrol* (2011) 22:239–45. doi:10.1681 ASN.2010050518

45. Brown EJ, Schlundorf JS, Becker DJ, Tsukaguchi H, Tonna SJ,uscini AK, et al. Mutations in the formin gene INF2 cause focal segmental glomerulo-
sclerosis. *Nat Genet* (2010) 42:727–6. doi:10.1038/ng.505

46. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulo-
sclerosis. *Nat Genet* (2000) 24:251–6. doi:10.1038/73456

47. Mele C, Iatropoulos P, Donadelli R, Calabria A, Maranta R, Cassis P, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal seg-
mental glomerulosclerosis. *Nat Genet* (2000) 24:251–6. doi:10.1038/73456

48. Lehtonen S, Zhao F, Lehtonen E. CD2-associated protein directly interacts with nephrin and associates with and enhances nephrin tyrosine phosphorylation and is necessary for foot process spreading in mouse models of podocyte injury. *Mol Cell Biol* (2010) 30:4125–36. doi:10.1128/MCB.00956-11

49. Santin S, Tazon-Vega B, Silva I, Cobo MA, Gimenez I, Ruiz P, et al. Clinical value of NPHS2 analysis in early- and adult-onset steroid-resistant nephrotic syndrome. *Clin J Am Soc Nephrol* (2011) 6:344–54. doi:10.2215/CJN.03770410

50. Buscher AK, Kranz B, Buscher R, Ilberg-Benndorf F, Dworniczak B, Pennekamp P, et al. Immunossuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. *Clin J Am Soc Nephrol* (2010) 5: 2075–84. doi:10.1681/CJN.01190210

51. Crawford BD, Gillies CE, Robertson CC, Crawford B, Vega-Warner V, Otto EA, et al. Using population genetics to interrogate the monogenic nephrotic syndrome diagnosis in a case cohort. *J Am Soc Nephrol* (2016) 27:1970–83. doi:10.1681 ASN.2015025054

52. Crawford BD, Gillies CE, Robertson CC, Kretzler M, Otto E, Vega-Wagner V, et al. Evaluating Mendelian nephrotic syndrome genes for evidence for risk alleles or oligogenicity that explain heritability. *Pediatr Nephrol* (2017) 32:467–76. doi:10.1007/s00467-016-3513-3

53. Friedman DJ, Kozlitina J, Genovese G, Jorg P, Pollak MR. Population-based risk assessment of APOL1 on renal disease. *J Am Soc Nephrol* (2011) 22:998–105. doi:10.1681/ASN.20101050519

54. Genovese G, Friedman DJ, Ross MD, Lecdordier L, Uzuareu P, Freedman BI, et al. Association of trypanotilic APOL1 variants with kidney disease in African Americans. *Science* (2010) 329:814–5. doi:10.1126/science.1193032

55. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-
associated nephropathy. *J Am Soc Nephrol* (2011) 22:129–37. doi:10.1681/ASN.2011040388

56. Laurin L-P, Lu M, Mottl AK, Blyth ER, Poulton CJ, Weck KE. Podocyte-
associated gene mutation screening in a heterogeneous cohort of patients with sporadic focal segmental glomerulosclerosis. *Nephrol Dial Transplant* (2014) 29:2062–9. doi:10.1093/ndt/gft532

57. Beckerman P, Bi-Karchin J, Park ASD, Qiu C, Dummer PD, Soomro I, et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. *Nat Med* (2017) 23:429–38. doi:10.1038/nm.4287

58. Hartlieb B, Warner N, Huber TR. Autophagy in glomerular health and dis-
ease. *Semin Nephrol* (2014) 34:42–52. doi:10.1016/j.smemph.2013.11.007

59. Kawakami T, Gomez IG, Ren S, Hudkins K, Roach A, Alpers CE, et al. Deficient autophagy results in mitochondrial dysfunction and FSGS. *J Am Soc Nephrol* (2015) 26:1040–52. doi:10.1681/ASN.2013111120

60. Bruggeman LA, Wu Z, Luo L, Madhavan SM, Konieczkowski M, Drewz PE, et al. APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease. *J Am Soc Nephrol* (2017) 28:3600–10. doi:10.1681 ASN.2015111220

61. Olabisi OA, Zhang YF, VerPlank L, Zahler N, DiBartolo S III, Heneghan JF, et al. APOL1 kidney disease risk variants enhance podocyte necrosis through compromising lysosomal function. *Proc Natl Acad Sci U S A* (2016) 113:830–7. doi:10.1073/pnas.152291113

62. Granado D, Muller D, Krausel V, Kruzel-Davila E, Schuberth C, Eschborn M, et al. Intracellular APOL1 risk variants cause cytotoxicity accompanied by energy depletion. *J Am Soc Nephrol* (2017) 28:3227–38. doi:10.1681/ASN.2016111120

63. Lan X, Jhaveri A, Cheng K, Wen H, Saleem MA, Mathieson PW, et al. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. *Am J Physiol Renal Physiol* (2014) 307:F326–36. doi:10.1152/ajprenal.00647.2013

64. Ma L, Chou JW, Snipes JA, Bharadwaj MS, Cranloch AL, Cheng D, et al. APOL1 renal-risk variants induce mitochondrial dysfunction. *J Am Soc Nephrol* (2017) 28:1093–105. doi:10.1681/ASN.2016050567

65. Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, Marinos NJ, et al. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immuno-
deficiency virus type 1 genes. *Proc Natl Acad Sci U S A* (1992) 89:1577–81. doi:10.1073/pnas.89.5.1577

66. Rosenstiel P, Gharavi A, D'Agati V, Klotman P. Transgenic and infectious animal models of HIV-associated nephropathy. *J Am Soc Nephrol* (2009) 20:2296–304. doi:10.1681/ASN.2008121230

67. Canaud G, Dejeux-Rainsford N, Avettand-Fenoil V, Wang J, Aicart S, et al. The kidney as a reservoir for HIV-1 after renal transplan-
tation. *Clin J Am Soc Nephrol* (2011) 6:344–54. doi:10.2215/CJN.03770410

68. Boston JA, Bruggeman LA, Ross MD, Jacobson J, Ross L, D'Agati VD, et al. Nephrapathy and establishment of a renal reservoir of HIV type 1
9. Schwimmer JA, Markowitz GS, Valeri A, Appel GB. Collapsing glomerulopathy: role in podocyte proliferation and maturation. *Kidney Int* (2000) 58:173–43. doi:10.1046/j.1523-1755.2000.00152.x

10. Djikman HBPM, Weening JJ, Smeets B, Verrijp KCN, van Kuppevelt TH, Luyckx VA, Bertram JF, Brenner BM, Fall C, Hoy WE, Ozanne SE, et al. Effect of fetal and childhood nutrition on kidney development and long-term risk of hypertension and kidney disease. *Lancet* (2013) 382:273–83. doi:10.1016/S0140-6736(13)60311-6

11. Schiffer M, Teng B, Gu C, Shchedrina VA, Kasaikina M, Pham VA, et al. Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. *Nat Med* (2015) 21:601–9. doi:10.1038/nm.3843

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2018 Wen, Shah and Campbell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.